LinkedIn

 آمار

تعداد نشریات20
تعداد شماره‌ها1,149
تعداد مقالات10,518
تعداد مشاهده مقاله45,415,573
تعداد دریافت فایل اصل مقاله11,291,392
Ashrafi, Farzaneh, Naeimi Tabiei, Mohammad, Mousavi, Sarah, Nematbakhsh, Mehdi, Sotoodehnasab, Parisa, Janbabaei, Ghasem. (1399). Does Vitamin E Mitigate Cisplatin-induced Nephrotoxicity in Cancer Patients: Results from a Randomized Placebo-Controlled Clinical Trial. سامانه مدیریت نشریات علمی, 11(2), 174-184. doi: 10.30476/mejc.2019.78710.0
Farzaneh Ashrafi; Mohammad Naeimi Tabiei; Sarah Mousavi; Mehdi Nematbakhsh; Parisa Sotoodehnasab; Ghasem Janbabaei. "Does Vitamin E Mitigate Cisplatin-induced Nephrotoxicity in Cancer Patients: Results from a Randomized Placebo-Controlled Clinical Trial". سامانه مدیریت نشریات علمی, 11, 2, 1399, 174-184. doi: 10.30476/mejc.2019.78710.0
Ashrafi, Farzaneh, Naeimi Tabiei, Mohammad, Mousavi, Sarah, Nematbakhsh, Mehdi, Sotoodehnasab, Parisa, Janbabaei, Ghasem. (1399). 'Does Vitamin E Mitigate Cisplatin-induced Nephrotoxicity in Cancer Patients: Results from a Randomized Placebo-Controlled Clinical Trial', سامانه مدیریت نشریات علمی, 11(2), pp. 174-184. doi: 10.30476/mejc.2019.78710.0
Ashrafi, Farzaneh, Naeimi Tabiei, Mohammad, Mousavi, Sarah, Nematbakhsh, Mehdi, Sotoodehnasab, Parisa, Janbabaei, Ghasem. Does Vitamin E Mitigate Cisplatin-induced Nephrotoxicity in Cancer Patients: Results from a Randomized Placebo-Controlled Clinical Trial. سامانه مدیریت نشریات علمی, 1399; 11(2): 174-184. doi: 10.30476/mejc.2019.78710.0

Does Vitamin E Mitigate Cisplatin-induced Nephrotoxicity in Cancer Patients: Results from a Randomized Placebo-Controlled Clinical Trial

Middle East Journal of Cancer
مقاله 6، دوره 11، شماره 2 - شماره پیاپی 42، تیر 2020، صفحه 174-184    اصل مقاله (1.31 M)
نوع مقاله: Original Article(s)
شناسه دیجیتال (DOI): 10.30476/mejc.2019.78710.0
نویسندگان
Farzaneh Ashrafi1؛ Mohammad Naeimi Tabiei2؛ Sarah Mousavi* 3؛ Mehdi Nematbakhsh4؛ Parisa Sotoodehnasab5؛ Ghasem Janbabaei6
1Department of Hematology and Oncology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
2Department of Hematology and Oncology, School of Medicine, Golestan University of Medical Sciences, Gorgan, Iran
3Department of Clinical Pharmacy and Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran
4Water and Electrolytes Research Center, Department of Physiology, Isfahan University of Medical Sciences, Isfahan, Iran
5School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran
6Department of Hematology and Oncology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
چکیده
Background: Cisplatin (CP) is a potent antineoplastic agent in the treatment of wide a range of cancers, but it is accompanied with nephrotoxicity, a major limiting side effect. The aim of the present study was to evaluate the possible protective effect of vitamin E in the prevention of CP-induced nephrotoxicity.
Method: In this randomized clinical trial, a total of 51 patients treated with CP chemotherapy were randomly assigned to receive vitamin E supplementation (400 Iu/ daily) (N=26) or placebo (N=25). Serum creatinine, glomerular filtration rate (GFR), and neutrophil gelatinase-associated lipocalin were measured prior to each chemotherapy cycle and one month after the cessation of the cycles.
Result: Compared to the baseline, a significant decrease was observed in the blood levels of neutrophil gelatinase-associated lipocalin and serum creatinine in the vitamin E group (P=0.001). GFR was not reduced in the vitamin E group (P=0.001), and vitamin E was generally tolerated well.
Conclusion: Our findings indicated that vitamin E exert protective effects against CP-induced nephrotoxicity, a finding which requires larger studies for confirmation.
کلیدواژه‌ها
Cisplatin؛ Nephrotoxicity؛ Neutrophil gelatinase-associated lipocalin؛ Vitamin E
آمار
تعداد مشاهده مقاله: 3,626
تعداد دریافت فایل اصل مقاله: 2,007


سامانه مدیریت نشریات علمی. قدرت گرفته از سیناوب